Detalles de la búsqueda
1.
Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma.
Radiology
; 298(2): 332-340, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33258745
2.
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
J Urol
; 203(4): 684-689, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31596672
3.
Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma.
J Clin Oncol
; 42(7): 774-778, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38194625
4.
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
J Immunother Cancer
; 12(4)2024 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38604810
5.
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients.
Clin Cancer Res
; 30(4): 803-813, 2024 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38060202
6.
A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS): Results from ECOG-ACRIN E1Z11.
Clin Cancer Res
; 2024 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38640040
7.
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
J Immunother Cancer
; 11(3)2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36948504
8.
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).
J Clin Oncol
; 40(25): 2913-2923, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35442713
9.
Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
JCO Precis Oncol
; 6: e2100424, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35138919
10.
Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent.
Mol Cancer Ther
; 20(8): 1454-1461, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34108261
11.
Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial.
J Thorac Oncol
; 16(6): 960-967, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33539971
12.
Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma.
Eur Urol
; 80(1): 20-31, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33707112
13.
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.
Clin Cancer Res
; 27(24): 6687-6695, 2021 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34759043
14.
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma.
Clin Cancer Res
; 27(5): 1371-1380, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33219016
15.
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.
Cancer Immunol Res
; 9(2): 156-169, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33229411
16.
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
Nat Med
; 26(6): 909-918, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32472114
Resultados
1 -
16
de 16
1
Próxima >
>>